stockrowSanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Sanofi (SNY) Revenue growth
Sanofi's revenue growth over the twelve months to 30 September 2026 was 26.3%, up 16.0 percentage points from fiscal 2025 (10.3%). Over the past ten years it has ranged from −14.6% (fiscal 2015) to 10.3% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers General industry median of 6.72% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 10.3% | 14.95 |
| FY2024 | −4.66% | (9.77) |
| FY2023 | 5.11% | 1.93 |
| FY2022 | 3.18% | (5.40) |
| FY2021 | 8.58% | 7.30 |
| FY2020 | 1.28% | 1.25 |
| FY2019 | 0.03% | (2.93) |
| FY2018 | 2.96% | (3.58) |
| FY2017 | 6.54% | 7.32 |
| FY2016 | −0.78% | 13.85 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 13.9% | (3.46) |
| Jun 2026 | 17.4% | (0.43) |
| Mar 2026 | 17.8% | (57.84) |
| Dec 2025 | 75.6% | 76.73 |
| 39 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| SNY Sanofi | 26.3% |
| NVO Novo Nordisk A/S compare | 13.2% |
| AMGN Amgen Inc. compare | 8.15% |
| AZN AstraZeneca PLC compare | 7.32% |
| GSK GSK PLC Sponsored ADR compare | 6.90% |
| GILD Gilead Sciences, Inc. compare | 6.54% |
| BMY Bristol Myers Squibb Company compare | 4.16% |
| NVS Novartis AG compare | 1.76% |
| PFE Pfizer Inc. compare | 1.34% |
| Drug Manufacturers General industry median | 6.72% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on SNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement